** Shares of Invion rise as much as 130.6% to A$0.415, posting their biggest intraday percentage gain since Oct. 28, 2021
** Stock hits its highest level since July 16
** Cancer treatment developer says the first patient has been dosed in the early-stage trial of its light absorbing material "INV043", aimed to treat non-melanoma skin cancer
** About 483,000 shares change hands, compared with the 30-day average volume of around 37,000
** Stock trims YTD losses to 30%, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。